Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas

Thrombosis Research

Volumn 128, Issue 6, 2011, Pages

  Harris, Leanne F ^a   Castro López, Vanessa ^a   Jenkins, P Vince ^b,c   O'Donnell, James S ^a,b,c   Killard, Anthony J ^d  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

AMC; chromogenic; factor Xa; fluorogenic; low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ARTICLE; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG MONITORING; DRUG STABILITY; FLUOROIMMUNOASSAY; HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANTICOAGULANTS; CHEMISTRY TECHNIQUES, ANALYTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; FLUORESCENT DYES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 82355173340     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.011     Document Type: Article

References (27)

1. J. Fareed, and J.M. Walenga Why differentiate low molecular weight heparins for venous thromboembolism? Thromb J 5 2007 8
2. J. Silvain, F. Beygui, A. Ankri, A. Bellemain-Appaix, A. Pena, and O. Barthelemy Enoxaparin Anticoagulation monitoring in the catheterization laboratory using a new bedside test J Am Coll Cardiol 55 2010 617 625
3. P. Rojnuckarin, B. Akkawat, and J. Juntiang Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring Clin Appl Thromb Hemost 16 2010 313 317
4. N.P. Clark Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency Thromb Res 123 2008 S58 S61
5. R. Abbate, A.M. Gori, A. Farsi, M. Attanasio, and G. Pepe Monitoring of low-molecular-weight heparins in cardiovascular disease Am J Cardiol 82 1998 33L 36L (Pubitemid 28413663)
6. W. Lim Using low molecular weight heparin in special patient populations J Thromb Thrombolysis 29 2010 233 240
7. S. Kitchen Problems in laboratory monitoring of heparin dosage Br J Haematol 111 2000 397 406
8. S.M. Bates, J.I. Weitz, M. Johnston, J. Hirsh, and J.S. Ginsberg Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin Arch Intern Med 161 2001 385 391 (Pubitemid 32116554)
9. G.T. Gerotziafas Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation J Thromb Haemost 5 2007 955 962 (Pubitemid 46691725)
10. H. Bounameaux, and P. De Moerloose Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No J Thromb Haemost 2 2004 551 554 (Pubitemid 40185676)
11. J. Hirsh, and R. Raschke Heparin and low-molecular-weight heparin - The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 188S 203S (Pubitemid 39297954)
12. A.N. Teien, M. Lie, and U. Abildgaard Assay of heparin in plasma using a chromogenic substrate for activated factor-10. Thromb Res 8 1976 413 416
13. L.F. Harris, V. Castro-López, N. Hammadi, J.S. O'Donnell, and A.J. Killard Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins Talanta 81 2010 1725 1730
14. H.C. Hemker, P. Giesen, R. Al Dieri, V. Regnault, E. de Smedt, and R. Wagenvoord Calibrated automated thrombin generation measurement in clotting plasma Pathophysiol Haemost Thromb 33 2003 4 15 (Pubitemid 37449290)
15. H.C. Hemker, P.L. Giesen, M. Ramjee, R. Wagenvoord, and S. Beguin The thrombogram: monitoring thrombin generation in platelet-rich plasma Thromb Haemost 83 2000 589 591 (Pubitemid 30201136)
16. J. Fareed, H.L. Messmore, J.M. Walenga, and E.W.J. Bermes Synthetic peptide substrates in hemostatic testing Crit Rev Clin Lab Sci 19 1983 71 134
17. T. Morita, H. Kato, S. Iwanaga, K. Takada, T. Kimura, and S. Sakakibara New fluorogenic substrates for alpha-thrombin, factor-Xa, kallikreins, and urokinase J Biochem 82 1977 1495 1498 (Pubitemid 8221894)
18. J.W. Eikelboom, and G.J. Hankey Low molecular weight heparins and heparinoids Med J Aust 177 2002 379 383 (Pubitemid 36104286)
19. B. Wood, and L. Fitzpatrick A review of the prevention and treatment of venous thromboembolism Formulary 45 2010 91 100
20. S. Kitchen, I. Jennings, T.A.L. Woods, and F.E. Preston Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage J Clin Pathol 49 1996 10 14 (Pubitemid 26034140)
21. E. ten Boekel, M. Boeck, G. Vrielink, R. Liem, H. Hendriks, and W. de Kieviet Detection of shortened activated partial thromboplastin times: An evaluation of different commercial reagents Thromb Res 121 2007 361 367
22. J. Horsti, H. Uppa, and J.A. Vilpo Poor agreement among prothrombin time international normalized ratio methods: Comparison of seven commercial reagents Clin Chem 51 2005 553 560 (Pubitemid 40300231)
23. S. Kuhle, P. Eulmesekian, B. Kavanagh, P. Massicotte, P. Vegh, and A. Lau Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children Haematologica 92 2007 554 557 (Pubitemid 350144302)
24. M.A. Smythe, and J.C. Mattson The heparin anti-Xa therapeutic range - Are we there yet? Chest 121 2002 303 304 (Pubitemid 34114270)
25. M.J. Kovacs, M. Keeney, K. MacKinnon, and E. Boyle Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin Clin Lab Haematol 21 1999 55 60 (Pubitemid 29143410)
26. S. Kitchen, R. Iampietro, A.M. Woolley, and F.E. Preston Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability Thromb Haemost 82 1999 1289 1293 (Pubitemid 29473794)
27. H.I. Flom-Halvorsen, E. Ovrum, M. Abdelnoor, S. Bjornsen, and F. Brosstad Assessment of heparin anticoagulation: Comparison of two commercially available methods Ann Thorac Surg 67 1999 1012 1016